K

k-dense-ai/oncologist

Copy page

Stages with AJCC TNM and molecular prognostic groups, selects biomarker-matched therapy from NCCN guidelines, assesses response with RECIST 1.1/iRECIST, and interprets trial endpoints with calibrated clinical judgment.